Patients with chronic kidney disease and atrial fibrillation had a higher rate of stroke or transient ischemic attack than those without CKD (1.4 vs. 0.6 per 100 person-years, p=0.045).
Observational (n=3,445)
How do anticoagulation dosing patterns and clinical outcomes differ between non-valvular atrial fibrillation patients with and without chronic kidney disease?
In patients with atrial fibrillation and chronic kidney disease, inappropriate NOAC dosing is common, and these patients face higher risks of stroke/TIA as well as aspirin-related minor bleeding.
Absolute Event Rate: 1.4% vs 0.6%
p-value: p=0.045
Abstract Purpose Dose reduction of non-vitamin K antagonist oral anticoagulants (NOACs) is indicated in patients with atrial fibrillation (AF) with renal impairment. This study investigated anticoagulation patterns and outcomes in patients with chronic kidney disease (CKD). Materials and methods In a prospective observational registry (CODE-AF), 3445 patients with non-valvular AF including 1129 with CKD (estimated glomerular filtration rate ≤ 60 mL min −1 1.73 m −2 ) were identified between June 1, 2016, and July 3, 2017. Results Compared with patients with no-CKD, patients with CKD more frequently had a high stroke risk (94.9% vs. 67.0%, p < 0.001) and higher NOAC usage rate (61.1% vs. 47.8%, p < 0.001). Among 718 patients with renal indication for dose reduction (RIDR), 7.5% were potentially overdosed. Among 2587 patients with no-RIDR, 79% were potentially underdosed. Compared with patients with no-RIDR, the underdose rates of dabigatran (0% vs. 88.6%, p = 0.001) and rivaroxaban (0% vs. 79.5%, p = 0.001) were lower in patients with RIDR. However, the underdose rate of apixaban was not different (62.5% vs. 53.9%, p = 0.089). The overdose rate of dabigatran (7.5% vs. 0%) and rivaroxaban (13.7% vs. 0%) was higher in RIDR than in no-RIDR patients. Stroke/transient ischemic attack was significantly higher in CKD patients (1.4 vs. 0.6 per 100 person-years, p = 0.045). Aspirin significantly increased minor bleeding in CKD patients compared with controls ( p = 0.037). Conclusion CKD patients might have a high stroke risk and NOAC usage rate. The underdose rate of NOACs decreased in CKD patients, except for apixaban. Aspirin significantly increased minor bleeding in CKD patients.
Choi et al. (Fri,) conducted a observational in non-valvular atrial fibrillation (n=3,445). NOACs vs. No chronic kidney disease was evaluated on Stroke/transient ischemic attack (p=0.045). Patients with chronic kidney disease and atrial fibrillation had a higher rate of stroke or transient ischemic attack than those without CKD (1.4 vs. 0.6 per 100 person-years, p=0.045).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: